Yes, paper should be soon but.. it's not a company that stands to benefit financially; it's one of the best run randomized trials. I don't see how they can ethically sit on this news given the findings. We also abruptly halt trials before the paper for similar levels of harms.
-
This Tweet is unavailable.
-
-
I think this is different from the too-quick releases or the peer-reviewed papers (in top journals, too!). A finding in the other direction would cause abrupt halt to trial and immediate warning, too. But yes they are probably not sleeping much and rushing the paper.
1 reply 0 retweets 0 likes -
This Tweet is unavailable.
-
Replying to @jayvanbavel @BrendanNyhan
I'm for wariness. We're in a weird environment, have to take things case by case. I was publicly warning against the (observational) Lancet study of HCQ harms weeks before it became clear that the data was likely fraudulent. Despite Lancet being top journal, it didn't seem right!
1 reply 0 retweets 0 likes -
OTOH, this one is not a company. Instead top-notch researchers and true and well-powered RCT. There is precedent for abrupt announcement, especially as governments/practitioners have to get ready. Prevent hoarding, etc. Still, agree, paper soon will guide clinical practice.
1 reply 0 retweets 0 likes
We've amazing preprints, we've had terrible peer-reviewed articles, we've had terrible (Harvard!) preprint study retweeted by POTUS (probably no amount of correction will work). It's not the usual environment.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.